English

NEKTAR THERAPEUTICS

EDGAR

NKTR Quarterly report (10-Q) · filed 2026-08-14

Annual consolidated revenue for 2025: about USD 55.23M, using the latest reported figures. The previous period, 2024, was about USD 98.43M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

10.1 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 10131000 USD Source

Operating margin

-417.94%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -42341000 USD Source
Revenue: 10131000 USD Source

Operating cash flow

-75.8 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -120068000 USD Source
Operating Cash Flow: -44298000 USD Source

Free cash flow

-75.9 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -120068000 USD Source
Operating Cash Flow: -44298000 USD Source
Capital Expenditure: 112000 USD Source
Capital Expenditure: 18000 USD Source

Cash and cash equivalents: 39.3 million USD 2026-06-30 Source
Exact value

39267000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 20.4 million shares 2026-06-30 Source
Exact value

20378832 shares

Reported share-count change

63.59% · 7.92 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

12457252 shares · 2025-06-30· Source
20378832 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

54.6 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 11790000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 55232000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 33425000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 10861000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 10131000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-157 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -35522000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -164076000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -127997000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -44904000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -40622000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-234 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -143552000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -94791000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -208511000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -143552000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -44298000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -120068000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -44298000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

244 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 153000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 39000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 171000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 153000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 18000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 112000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 18000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-234 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -143552000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -94791000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -208511000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -143552000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -44298000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -120068000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -44298000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 153000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 39000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 171000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 153000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 18000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 112000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 18000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-14.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-43.9%

Prior period

USD 98.43 million

2024-01-01 – 2024-12-31
Current period

USD 55.23 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

55232000 − 98427000 = -43195000 USD

98427000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
55232000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · NEKTAR THERAPEUTICS · 2025-12-31 NEKTAR THERAPEUTICS (edgar:906709) Year-over-year change in Revenue: -43195000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 55232000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#3249987 Filing: 000119312526104547 Input fundies:Revenue: 98427000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#3251769 Filing: 000119312526104547
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 45.12 million

Prior period

−USD 118.96 million

2024-01-01 – 2024-12-31
Current period

−USD 164.08 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-164076000 − -118961000 = -45115000 USD

-118961000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-164076000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · NEKTAR THERAPEUTICS · 2025-12-31 NEKTAR THERAPEUTICS (edgar:906709) Year-over-year change in Net income: -45115000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -164076000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#3197131 Filing: 000119312526104547 Input fundies:NetIncome: -118961000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#3198992 Filing: 000119312526104547
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 32.8 million

Prior period

−USD 175.71 million

2024-01-01 – 2024-12-31
Current period

−USD 208.51 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-208511000 − -175709000 = -32802000 USD

-175709000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-208511000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · NEKTAR THERAPEUTICS · 2025-12-31 NEKTAR THERAPEUTICS (edgar:906709) Year-over-year change in Operating cash flow: -32802000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -208511000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#1719357 Filing: 000119312526104547 Input fundies:OperatingCashFlow: -175709000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#1721213 Filing: 000119312526104547
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-88.4%

Prior period

USD 1.47 million

2024-01-01 – 2024-12-31
Current period

USD 171,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

171000 − 1468000 = -1297000 USD

1468000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
171000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · NEKTAR THERAPEUTICS · 2025-12-31 NEKTAR THERAPEUTICS (edgar:906709) Year-over-year change in Capital expenditure: -1297000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 171000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#1737908 Filing: 000119312526104547 Input fundies:CapitalExpenditure: 1468000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#1739647 Filing: 000119312526104547
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 55.23 million 100% of revenue
Operating costs Derived USD 195.33 million 354% of revenue
Operating income −USD 140.1 million −254% of revenue
Tax, interest and other Derived USD 23.97 million 43% of revenue
Net income −USD 164.08 million −297% of revenue

Cash

Operating cash flow −USD 208.51 million −378% of revenue
Capital expenditure USD 171,000 0.3% of revenue
Free cash flow Derived −USD 208.68 million −378% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 168% of revenue.
2017 Operating loss: operating costs were 119% of revenue.
2018 57%42%
2019 Operating loss: operating costs were 484% of revenue.
2020 Operating loss: operating costs were 378% of revenue.
2021 Operating loss: operating costs were 538% of revenue.
2022 Operating loss: operating costs were 509% of revenue.
2023 Operating loss: operating costs were 393% of revenue.
2024 Operating loss: operating costs were 207% of revenue.
2025 Operating loss: operating costs were 354% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	165436000	278291000 Derived	-112855000	40669000 Derived	-153524000	-123416000 Derived	Source 2016-01-01 – 2016-12-31: 165436000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -112855000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -153524000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -117024000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 6392000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	307711000	367353000 Derived	-59642000	37050000 Derived	-96692000	-90090000 Derived	Source 2017-01-01 – 2017-12-31: 307711000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -59642000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -96692000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -80414000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 9676000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	1193323000	505391000 Derived	687932000	6619000 Derived	681313000	703975000 Derived	Source 2018-01-01 – 2018-12-31: 1193323000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: 687932000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: 681313000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 718214000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 14239000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	114617000	554652000 Derived	-440035000	632000 Derived	-440667000	-354966000 Derived	Source 2019-01-01 – 2019-12-31: 114617000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -440035000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -440667000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -328681000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 26285000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	152915000	578026000 Derived	-425111000	19329000 Derived	-444440000	-320545000 Derived	Source 2020-01-01 – 2020-12-31: 152915000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -425111000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -444440000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -313287000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 7258000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	101907000	548010000 Derived	-446103000	77734000 Derived	-523837000	-427649000 Derived	Source 2021-01-01 – 2021-12-31: 101907000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -446103000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -523837000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -412660000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 14989000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	92055000	468221000 Derived	-376166000	-7968000 Derived	-368198000	-309683000 Derived	Source 2022-01-01 – 2022-12-31: 92055000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -376166000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -368198000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -304007000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 5676000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	90122000	353806000 Derived	-263684000	12372000 Derived	-276056000	-193471000 Derived	Source 2023-01-01 – 2023-12-31: 90122000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -263684000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -276056000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -192606000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 865000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	98427000	203625000 Derived	-105198000	13763000 Derived	-118961000	-177177000 Derived	Source 2024-01-01 – 2024-12-31: 98427000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -105198000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -118961000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -175709000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 1468000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	55232000	195334000 Derived	-140102000	23974000 Derived	-164076000	-208682000 Derived	Source 2025-01-01 – 2025-12-31: 55232000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -140102000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -164076000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -208511000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 171000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 55.2M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	165436000	Revenue: 165436000 Open source
20172017-12-31	Revenue	307711000	Revenue: 307711000 Open source
20182018-12-31	Revenue	1193323000	Revenue: 1193323000 Open source
20192019-12-31	Revenue	114617000	Revenue: 114617000 Open source
20202020-12-31	Revenue	152915000	Revenue: 152915000 Open source
20212021-12-31	Revenue	101907000	Revenue: 101907000 Open source
20222022-12-31	Revenue	92055000	Revenue: 92055000 Open source
20232023-12-31	Revenue	90122000	Revenue: 90122000 Open source
20242024-12-31	Revenue	98427000	Revenue: 98427000 Open source
20252025-12-31	Revenue	55232000	Revenue: 55232000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-43.9% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	-28.3%	Revenue: 165436000 Open source Revenue: 230784000 Open source
20172017-12-31	Year over year	86%	Revenue: 307711000 Open source Revenue: 165436000 Open source
20182018-12-31	Year over year	287.8%	Revenue: 1193323000 Open source Revenue: 307711000 Open source
20192019-12-31	Year over year	-90.4%	Revenue: 114617000 Open source Revenue: 1193323000 Open source
20202020-12-31	Year over year	33.4%	Revenue: 152915000 Open source Revenue: 114617000 Open source
20212021-12-31	Year over year	-33.4%	Revenue: 101907000 Open source Revenue: 152915000 Open source
20222022-12-31	Year over year	-9.7%	Revenue: 92055000 Open source Revenue: 101907000 Open source
20232023-12-31	Year over year	-2.1%	Revenue: 90122000 Open source Revenue: 92055000 Open source
20242024-12-31	Year over year	9.2%	Revenue: 98427000 Open source Revenue: 90122000 Open source
20252025-12-31	Year over year	-43.9%	Revenue: 55232000 Open source Revenue: 98427000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -253.7% 2025

Net margin -297.1% 2025

Free cash flow margin -377.8% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-68.2%	Operating Income: -112855000 Open source Revenue: 165436000 Open source
20172017-12-31	Operating margin	-19.4%	Operating Income: -59642000 Open source Revenue: 307711000 Open source
20182018-12-31	Operating margin	57.6%	Operating Income: 687932000 Open source Revenue: 1193323000 Open source
20192019-12-31	Operating margin	-383.9%	Operating Income: -440035000 Open source Revenue: 114617000 Open source
20202020-12-31	Operating margin	-278%	Operating Income: -425111000 Open source Revenue: 152915000 Open source
20212021-12-31	Operating margin	-437.8%	Operating Income: -446103000 Open source Revenue: 101907000 Open source
20222022-12-31	Operating margin	-408.6%	Operating Income: -376166000 Open source Revenue: 92055000 Open source
20232023-12-31	Operating margin	-292.6%	Operating Income: -263684000 Open source Revenue: 90122000 Open source
20242024-12-31	Operating margin	-106.9%	Operating Income: -105198000 Open source Revenue: 98427000 Open source
20252025-12-31	Operating margin	-253.7%	Operating Income: -140102000 Open source Revenue: 55232000 Open source
20162016-12-31	Net margin	-92.8%	Net Income: -153524000 Open source Revenue: 165436000 Open source
20172017-12-31	Net margin	-31.4%	Net Income: -96692000 Open source Revenue: 307711000 Open source
20182018-12-31	Net margin	57.1%	Net Income: 681313000 Open source Revenue: 1193323000 Open source
20192019-12-31	Net margin	-384.5%	Net Income: -440667000 Open source Revenue: 114617000 Open source
20202020-12-31	Net margin	-290.6%	Net Income: -444440000 Open source Revenue: 152915000 Open source
20212021-12-31	Net margin	-514%	Net Income: -523837000 Open source Revenue: 101907000 Open source
20222022-12-31	Net margin	-400%	Net Income: -368198000 Open source Revenue: 92055000 Open source
20232023-12-31	Net margin	-306.3%	Net Income: -276056000 Open source Revenue: 90122000 Open source
20242024-12-31	Net margin	-120.9%	Net Income: -118961000 Open source Revenue: 98427000 Open source
20252025-12-31	Net margin	-297.1%	Net Income: -164076000 Open source Revenue: 55232000 Open source
20162016-12-31	Free cash flow margin	-74.6%	Revenue: 165436000 Open source Operating Cash Flow: -117024000 Open source Capital Expenditure: 6392000 Open source
20172017-12-31	Free cash flow margin	-29.3%	Revenue: 307711000 Open source Operating Cash Flow: -80414000 Open source Capital Expenditure: 9676000 Open source
20182018-12-31	Free cash flow margin	59%	Revenue: 1193323000 Open source Operating Cash Flow: 718214000 Open source Capital Expenditure: 14239000 Open source
20192019-12-31	Free cash flow margin	-309.7%	Revenue: 114617000 Open source Operating Cash Flow: -328681000 Open source Capital Expenditure: 26285000 Open source
20202020-12-31	Free cash flow margin	-209.6%	Revenue: 152915000 Open source Operating Cash Flow: -313287000 Open source Capital Expenditure: 7258000 Open source
20212021-12-31	Free cash flow margin	-419.6%	Revenue: 101907000 Open source Operating Cash Flow: -412660000 Open source Capital Expenditure: 14989000 Open source
20222022-12-31	Free cash flow margin	-336.4%	Revenue: 92055000 Open source Operating Cash Flow: -304007000 Open source Capital Expenditure: 5676000 Open source
20232023-12-31	Free cash flow margin	-214.7%	Revenue: 90122000 Open source Operating Cash Flow: -192606000 Open source Capital Expenditure: 865000 Open source
20242024-12-31	Free cash flow margin	-180%	Revenue: 98427000 Open source Operating Cash Flow: -175709000 Open source Capital Expenditure: 1468000 Open source
20252025-12-31	Free cash flow margin	-377.8%	Revenue: 55232000 Open source Operating Cash Flow: -208511000 Open source Capital Expenditure: 171000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -208.5M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-117024000	Operating Cash Flow: -117024000 Open source
20172017-12-31	Operating cash flow	-80414000	Operating Cash Flow: -80414000 Open source
20182018-12-31	Operating cash flow	718214000	Operating Cash Flow: 718214000 Open source
20192019-12-31	Operating cash flow	-328681000	Operating Cash Flow: -328681000 Open source
20202020-12-31	Operating cash flow	-313287000	Operating Cash Flow: -313287000 Open source
20212021-12-31	Operating cash flow	-412660000	Operating Cash Flow: -412660000 Open source
20222022-12-31	Operating cash flow	-304007000	Operating Cash Flow: -304007000 Open source
20232023-12-31	Operating cash flow	-192606000	Operating Cash Flow: -192606000 Open source
20242024-12-31	Operating cash flow	-175709000	Operating Cash Flow: -175709000 Open source
20252025-12-31	Operating cash flow	-208511000	Operating Cash Flow: -208511000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -208.7M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-123416000	Operating Cash Flow: -117024000 Open source Capital Expenditure: 6392000 Open source
20172017-12-31	Free cash flow	-90090000	Operating Cash Flow: -80414000 Open source Capital Expenditure: 9676000 Open source
20182018-12-31	Free cash flow	703975000	Operating Cash Flow: 718214000 Open source Capital Expenditure: 14239000 Open source
20192019-12-31	Free cash flow	-354966000	Operating Cash Flow: -328681000 Open source Capital Expenditure: 26285000 Open source
20202020-12-31	Free cash flow	-320545000	Operating Cash Flow: -313287000 Open source Capital Expenditure: 7258000 Open source
20212021-12-31	Free cash flow	-427649000	Operating Cash Flow: -412660000 Open source Capital Expenditure: 14989000 Open source
20222022-12-31	Free cash flow	-309683000	Operating Cash Flow: -304007000 Open source Capital Expenditure: 5676000 Open source
20232023-12-31	Free cash flow	-193471000	Operating Cash Flow: -192606000 Open source Capital Expenditure: 865000 Open source
20242024-12-31	Free cash flow	-177177000	Operating Cash Flow: -175709000 Open source Capital Expenditure: 1468000 Open source
20252025-12-31	Free cash flow	-208682000	Operating Cash Flow: -208511000 Open source Capital Expenditure: 171000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

68% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	84.5%	Total Liabilities: 480746000 Open source Total Assets: 568871000 Open source
20172017-12-31	Liabilities / assets	82.7%	Total Liabilities: 421038000 Open source Total Assets: 508866000 Open source
20182018-12-31	Liabilities / assets	20.1%	Total Liabilities: 432597000 Open source Total Assets: 2150172000 Open source
20192019-12-31	Liabilities / assets	28.9%	Total Liabilities: 571965000 Open source Total Assets: 1977356000 Open source
20202020-12-31	Liabilities / assets	30%	Total Liabilities: 461472000 Open source Total Assets: 1538767000 Open source
20212021-12-31	Liabilities / assets	39.2%	Total Liabilities: 437681000 Open source Total Assets: 1117189000 Open source
20222022-12-31	Liabilities / assets	48.4%	Total Liabilities: 343962000 Open source Total Assets: 710600000 Open source
20232023-12-31	Liabilities / assets	67.1%	Total Liabilities: 267046000 Open source Total Assets: 398033000 Open source
20242024-12-31	Liabilities / assets	80%	Total Liabilities: 243113000 Open source Total Assets: 303850000 Open source
20252025-12-31	Liabilities / assets	68%	Total Liabilities: 190574000 Open source Total Assets: 280406000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

4.97× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	5.9×	Current Assets: 425952000 Open source Current Liabilities: 72222000 Open source
20172017-12-31	Current assets / current liabilities	5.82×	Current Assets: 326820000 Open source Current Liabilities: 56163000 Open source
20182018-12-31	Current assets / current liabilities	17.53×	Current Assets: 1437687000 Open source Current Liabilities: 82002000 Open source
20192019-12-31	Current assets / current liabilities	4.02×	Current Assets: 1421550000 Open source Current Liabilities: 353893000 Open source
20202020-12-31	Current assets / current liabilities	9.83×	Current Assets: 1138005000 Open source Current Liabilities: 115779000 Open source
20212021-12-31	Current assets / current liabilities	9.34×	Current Assets: 795581000 Open source Current Liabilities: 85200000 Open source
20222022-12-31	Current assets / current liabilities	8×	Current Assets: 545968000 Open source Current Liabilities: 68204000 Open source
20232023-12-31	Current assets / current liabilities	6.45×	Current Assets: 330701000 Open source Current Liabilities: 51269000 Open source
20242024-12-31	Current assets / current liabilities	4.26×	Current Assets: 261292000 Open source Current Liabilities: 61400000 Open source
20252025-12-31	Current assets / current liabilities	4.97×	Current Assets: 266266000 Open source Current Liabilities: 53536000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 153.52 million Exact value Exact value: -153524000 USD 2016-01-01 – 2016-12-31: -153524000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NEKTAR THERAPEUTICS · 2016-12-31 NEKTAR THERAPEUTICS (edgar:906709) Net Income: -153524000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -153524000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000156459019005639/nktr-20181231.xml#199569 Filing: 000156459019005639 The citation records this snapshot. The page link may show a newer release later.	−USD 117.02 million Exact value Exact value: -117024000 USD 2016-01-01 – 2016-12-31: -117024000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NEKTAR THERAPEUTICS · 2016-12-31 NEKTAR THERAPEUTICS (edgar:906709) Operating Cash Flow: -117024000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -117024000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000156459019005639/nktr-20181231.xml#240020 Filing: 000156459019005639 The citation records this snapshot. The page link may show a newer release later.	USD 6.39 million Exact value Exact value: 6392000 USD 2016-01-01 – 2016-12-31: 6392000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NEKTAR THERAPEUTICS · 2016-12-31 NEKTAR THERAPEUTICS (edgar:906709) Capital Expenditure: 6392000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6392000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000156459019005639/nktr-20181231.xml#242787 Filing: 000156459019005639 The citation records this snapshot. The page link may show a newer release later.	−USD 123.42 million Calculation and evidence -117024000 − 6392000 USD Exact free cash flow: -123416000 USD 2016-01-01 – 2016-12-31: -117024000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 6392000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NEKTAR THERAPEUTICS · 2016-12-31 NEKTAR THERAPEUTICS (edgar:906709) Free cash flow: -123416000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -117024000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000156459019005639/nktr-20181231.xml#240020 Filing: 000156459019005639 Input fundies:CapitalExpenditure: 6392000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000156459019005639/nktr-20181231.xml#242787 Filing: 000156459019005639 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 96.69 million Exact value Exact value: -96692000 USD 2017-01-01 – 2017-12-31: -96692000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NEKTAR THERAPEUTICS · 2017-12-31 NEKTAR THERAPEUTICS (edgar:906709) Net Income: -96692000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -96692000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr-20191231x10k.htm#1355038 Filing: 000090670920000004 The citation records this snapshot. The page link may show a newer release later.	−USD 80.41 million Exact value Exact value: -80414000 USD 2017-01-01 – 2017-12-31: -80414000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NEKTAR THERAPEUTICS · 2017-12-31 NEKTAR THERAPEUTICS (edgar:906709) Operating Cash Flow: -80414000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -80414000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr-20191231x10k.htm#1480962 Filing: 000090670920000004 The citation records this snapshot. The page link may show a newer release later.	USD 9.68 million Exact value Exact value: 9676000 USD 2017-01-01 – 2017-12-31: 9676000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NEKTAR THERAPEUTICS · 2017-12-31 NEKTAR THERAPEUTICS (edgar:906709) Capital Expenditure: 9676000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9676000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr-20191231x10k.htm#1493759 Filing: 000090670920000004 The citation records this snapshot. The page link may show a newer release later.	−USD 90.09 million Calculation and evidence -80414000 − 9676000 USD Exact free cash flow: -90090000 USD 2017-01-01 – 2017-12-31: -80414000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 9676000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NEKTAR THERAPEUTICS · 2017-12-31 NEKTAR THERAPEUTICS (edgar:906709) Free cash flow: -90090000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -80414000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr-20191231x10k.htm#1480962 Filing: 000090670920000004 Input fundies:CapitalExpenditure: 9676000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr-20191231x10k.htm#1493759 Filing: 000090670920000004 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	USD 681.31 million Exact value Exact value: 681313000 USD 2018-01-01 – 2018-12-31: 681313000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NEKTAR THERAPEUTICS · 2018-12-31 NEKTAR THERAPEUTICS (edgar:906709) Net Income: 681313000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: 681313000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670921000005/nktr-20201231.htm#1158232 Filing: 000090670921000005 The citation records this snapshot. The page link may show a newer release later.	USD 718.21 million Exact value Exact value: 718214000 USD 2018-01-01 – 2018-12-31: 718214000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NEKTAR THERAPEUTICS · 2018-12-31 NEKTAR THERAPEUTICS (edgar:906709) Operating Cash Flow: 718214000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 718214000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670921000005/nktr-20201231.htm#1312035 Filing: 000090670921000005 The citation records this snapshot. The page link may show a newer release later.	USD 14.24 million Exact value Exact value: 14239000 USD 2018-01-01 – 2018-12-31: 14239000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NEKTAR THERAPEUTICS · 2018-12-31 NEKTAR THERAPEUTICS (edgar:906709) Capital Expenditure: 14239000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 14239000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670921000005/nktr-20201231.htm#1325531 Filing: 000090670921000005 The citation records this snapshot. The page link may show a newer release later.	USD 703.98 million Calculation and evidence 718214000 − 14239000 USD Exact free cash flow: 703975000 USD 2018-01-01 – 2018-12-31: 718214000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 14239000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NEKTAR THERAPEUTICS · 2018-12-31 NEKTAR THERAPEUTICS (edgar:906709) Free cash flow: 703975000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 718214000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670921000005/nktr-20201231.htm#1312035 Filing: 000090670921000005 Input fundies:CapitalExpenditure: 14239000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670921000005/nktr-20201231.htm#1325531 Filing: 000090670921000005 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 440.67 million Exact value Exact value: -440667000 USD 2019-01-01 – 2019-12-31: -440667000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NEKTAR THERAPEUTICS · 2019-12-31 NEKTAR THERAPEUTICS (edgar:906709) Net Income: -440667000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -440667000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670922000005/nktr-20211231.htm#1089223 Filing: 000090670922000005 The citation records this snapshot. The page link may show a newer release later.	−USD 328.68 million Exact value Exact value: -328681000 USD 2019-01-01 – 2019-12-31: -328681000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NEKTAR THERAPEUTICS · 2019-12-31 NEKTAR THERAPEUTICS (edgar:906709) Operating Cash Flow: -328681000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -328681000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670922000005/nktr-20211231.htm#1245266 Filing: 000090670922000005 The citation records this snapshot. The page link may show a newer release later.	USD 26.29 million Exact value Exact value: 26285000 USD 2019-01-01 – 2019-12-31: 26285000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NEKTAR THERAPEUTICS · 2019-12-31 NEKTAR THERAPEUTICS (edgar:906709) Capital Expenditure: 26285000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26285000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670922000005/nktr-20211231.htm#1258850 Filing: 000090670922000005 The citation records this snapshot. The page link may show a newer release later.	−USD 354.97 million Calculation and evidence -328681000 − 26285000 USD Exact free cash flow: -354966000 USD 2019-01-01 – 2019-12-31: -328681000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 26285000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NEKTAR THERAPEUTICS · 2019-12-31 NEKTAR THERAPEUTICS (edgar:906709) Free cash flow: -354966000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -328681000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670922000005/nktr-20211231.htm#1245266 Filing: 000090670922000005 Input fundies:CapitalExpenditure: 26285000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670922000005/nktr-20211231.htm#1258850 Filing: 000090670922000005 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 444.44 million Exact value Exact value: -444440000 USD 2020-01-01 – 2020-12-31: -444440000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NEKTAR THERAPEUTICS · 2020-12-31 NEKTAR THERAPEUTICS (edgar:906709) Net Income: -444440000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -444440000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670923000004/nktr-20221231.htm#948165 Filing: 000090670923000004 The citation records this snapshot. The page link may show a newer release later.	−USD 313.29 million Exact value Exact value: -313287000 USD 2020-01-01 – 2020-12-31: -313287000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NEKTAR THERAPEUTICS · 2020-12-31 NEKTAR THERAPEUTICS (edgar:906709) Operating Cash Flow: -313287000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -313287000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670923000004/nktr-20221231.htm#1113691 Filing: 000090670923000004 The citation records this snapshot. The page link may show a newer release later.	USD 7.26 million Exact value Exact value: 7258000 USD 2020-01-01 – 2020-12-31: 7258000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NEKTAR THERAPEUTICS · 2020-12-31 NEKTAR THERAPEUTICS (edgar:906709) Capital Expenditure: 7258000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7258000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670923000004/nktr-20221231.htm#1127271 Filing: 000090670923000004 The citation records this snapshot. The page link may show a newer release later.	−USD 320.55 million Calculation and evidence -313287000 − 7258000 USD Exact free cash flow: -320545000 USD 2020-01-01 – 2020-12-31: -313287000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 7258000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NEKTAR THERAPEUTICS · 2020-12-31 NEKTAR THERAPEUTICS (edgar:906709) Free cash flow: -320545000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -313287000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670923000004/nktr-20221231.htm#1113691 Filing: 000090670923000004 Input fundies:CapitalExpenditure: 7258000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000090670923000004/nktr-20221231.htm#1127271 Filing: 000090670923000004 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 523.84 million Exact value Exact value: -523837000 USD 2021-01-01 – 2021-12-31: -523837000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NEKTAR THERAPEUTICS · 2021-12-31 NEKTAR THERAPEUTICS (edgar:906709) Net Income: -523837000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -523837000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000095017024026249/nktr-20231231.htm#1208045 Filing: 000095017024026249 The citation records this snapshot. The page link may show a newer release later.	−USD 412.66 million Exact value Exact value: -412660000 USD 2021-01-01 – 2021-12-31: -412660000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NEKTAR THERAPEUTICS · 2021-12-31 NEKTAR THERAPEUTICS (edgar:906709) Operating Cash Flow: -412660000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -412660000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000095017024026249/nktr-20231231.htm#1449961 Filing: 000095017024026249 The citation records this snapshot. The page link may show a newer release later.	USD 14.99 million Exact value Exact value: 14989000 USD 2021-01-01 – 2021-12-31: 14989000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NEKTAR THERAPEUTICS · 2021-12-31 NEKTAR THERAPEUTICS (edgar:906709) Capital Expenditure: 14989000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 14989000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000095017024026249/nktr-20231231.htm#1469277 Filing: 000095017024026249 The citation records this snapshot. The page link may show a newer release later.	−USD 427.65 million Calculation and evidence -412660000 − 14989000 USD Exact free cash flow: -427649000 USD 2021-01-01 – 2021-12-31: -412660000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 14989000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NEKTAR THERAPEUTICS · 2021-12-31 NEKTAR THERAPEUTICS (edgar:906709) Free cash flow: -427649000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -412660000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000095017024026249/nktr-20231231.htm#1449961 Filing: 000095017024026249 Input fundies:CapitalExpenditure: 14989000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000095017024026249/nktr-20231231.htm#1469277 Filing: 000095017024026249 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 368.2 million Exact value Exact value: -368198000 USD 2022-01-01 – 2022-12-31: -368198000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NEKTAR THERAPEUTICS · 2022-12-31 NEKTAR THERAPEUTICS (edgar:906709) Net Income: -368198000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -368198000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000095017024026249/nktr-20231231.htm#1206730 Filing: 000095017024026249 The citation records this snapshot. The page link may show a newer release later.	−USD 304.01 million Exact value Exact value: -304007000 USD 2022-01-01 – 2022-12-31: -304007000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NEKTAR THERAPEUTICS · 2022-12-31 NEKTAR THERAPEUTICS (edgar:906709) Operating Cash Flow: -304007000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -304007000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000095017024026249/nktr-20231231.htm#1448551 Filing: 000095017024026249 The citation records this snapshot. The page link may show a newer release later.	USD 5.68 million Exact value Exact value: 5676000 USD 2022-01-01 – 2022-12-31: 5676000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NEKTAR THERAPEUTICS · 2022-12-31 NEKTAR THERAPEUTICS (edgar:906709) Capital Expenditure: 5676000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5676000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000095017024026249/nktr-20231231.htm#1467982 Filing: 000095017024026249 The citation records this snapshot. The page link may show a newer release later.	−USD 309.68 million Calculation and evidence -304007000 − 5676000 USD Exact free cash flow: -309683000 USD 2022-01-01 – 2022-12-31: -304007000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 5676000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NEKTAR THERAPEUTICS · 2022-12-31 NEKTAR THERAPEUTICS (edgar:906709) Free cash flow: -309683000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -304007000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000095017024026249/nktr-20231231.htm#1448551 Filing: 000095017024026249 Input fundies:CapitalExpenditure: 5676000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000095017024026249/nktr-20231231.htm#1467982 Filing: 000095017024026249 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 276.06 million Exact value Exact value: -276056000 USD 2023-01-01 – 2023-12-31: -276056000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NEKTAR THERAPEUTICS · 2023-12-31 NEKTAR THERAPEUTICS (edgar:906709) Net Income: -276056000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -276056000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000095017025039389/nktr-20241231.htm#1334687 Filing: 000095017025039389 The citation records this snapshot. The page link may show a newer release later.	−USD 192.61 million Exact value Exact value: -192606000 USD 2023-01-01 – 2023-12-31: -192606000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NEKTAR THERAPEUTICS · 2023-12-31 NEKTAR THERAPEUTICS (edgar:906709) Operating Cash Flow: -192606000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -192606000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000095017025039389/nktr-20241231.htm#1598600 Filing: 000095017025039389 The citation records this snapshot. The page link may show a newer release later.	USD 865,000 Exact value Exact value: 865000 USD 2023-01-01 – 2023-12-31: 865000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NEKTAR THERAPEUTICS · 2023-12-31 NEKTAR THERAPEUTICS (edgar:906709) Capital Expenditure: 865000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 865000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000095017025039389/nktr-20241231.htm#1615600 Filing: 000095017025039389 The citation records this snapshot. The page link may show a newer release later.	−USD 193.47 million Calculation and evidence -192606000 − 865000 USD Exact free cash flow: -193471000 USD 2023-01-01 – 2023-12-31: -192606000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 865000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NEKTAR THERAPEUTICS · 2023-12-31 NEKTAR THERAPEUTICS (edgar:906709) Free cash flow: -193471000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -192606000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000095017025039389/nktr-20241231.htm#1598600 Filing: 000095017025039389 Input fundies:CapitalExpenditure: 865000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000095017025039389/nktr-20241231.htm#1615600 Filing: 000095017025039389 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 118.96 million Exact value Exact value: -118961000 USD 2024-01-01 – 2024-12-31: -118961000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NEKTAR THERAPEUTICS · 2024-12-31 NEKTAR THERAPEUTICS (edgar:906709) Net Income: -118961000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -118961000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#3198992 Filing: 000119312526104547 The citation records this snapshot. The page link may show a newer release later.	−USD 175.71 million Exact value Exact value: -175709000 USD 2024-01-01 – 2024-12-31: -175709000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NEKTAR THERAPEUTICS · 2024-12-31 NEKTAR THERAPEUTICS (edgar:906709) Operating Cash Flow: -175709000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -175709000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#1721213 Filing: 000119312526104547 The citation records this snapshot. The page link may show a newer release later.	USD 1.47 million Exact value Exact value: 1468000 USD 2024-01-01 – 2024-12-31: 1468000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NEKTAR THERAPEUTICS · 2024-12-31 NEKTAR THERAPEUTICS (edgar:906709) Capital Expenditure: 1468000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1468000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#1739647 Filing: 000119312526104547 The citation records this snapshot. The page link may show a newer release later.	−USD 177.18 million Calculation and evidence -175709000 − 1468000 USD Exact free cash flow: -177177000 USD 2024-01-01 – 2024-12-31: -175709000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 1468000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NEKTAR THERAPEUTICS · 2024-12-31 NEKTAR THERAPEUTICS (edgar:906709) Free cash flow: -177177000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -175709000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#1721213 Filing: 000119312526104547 Input fundies:CapitalExpenditure: 1468000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#1739647 Filing: 000119312526104547 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 164.08 million Exact value Exact value: -164076000 USD 2025-01-01 – 2025-12-31: -164076000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NEKTAR THERAPEUTICS · 2025-12-31 NEKTAR THERAPEUTICS (edgar:906709) Net Income: -164076000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -164076000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#3197131 Filing: 000119312526104547 The citation records this snapshot. The page link may show a newer release later.	−USD 208.51 million Exact value Exact value: -208511000 USD 2025-01-01 – 2025-12-31: -208511000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NEKTAR THERAPEUTICS · 2025-12-31 NEKTAR THERAPEUTICS (edgar:906709) Operating Cash Flow: -208511000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -208511000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#1719357 Filing: 000119312526104547 The citation records this snapshot. The page link may show a newer release later.	USD 171,000 Exact value Exact value: 171000 USD 2025-01-01 – 2025-12-31: 171000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NEKTAR THERAPEUTICS · 2025-12-31 NEKTAR THERAPEUTICS (edgar:906709) Capital Expenditure: 171000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 171000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#1737908 Filing: 000119312526104547 The citation records this snapshot. The page link may show a newer release later.	−USD 208.68 million Calculation and evidence -208511000 − 171000 USD Exact free cash flow: -208682000 USD 2025-01-01 – 2025-12-31: -208511000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 171000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NEKTAR THERAPEUTICS · 2025-12-31 NEKTAR THERAPEUTICS (edgar:906709) Free cash flow: -208682000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:28:07Z Snapshot: bda318d56204e0e089a903471ec5d37adff261392fdf612cb9e2797befb94d5c Dimensions: Consolidated View: https://fundies.io/companies/edgar/906709?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -208511000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#1719357 Filing: 000119312526104547 Input fundies:CapitalExpenditure: 171000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm#1737908 Filing: 000119312526104547 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

271 filings · 5,552 latest values · 5,552 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000906709, 906709, NKTR, edgar:906709

Also known as INHALE THERAPEUTIC SYSTEMS, INHALE THERAPEUTIC SYSTEMS INC, NEKTAR THERAPEUTICS

NEKTAR THERAPEUTICS

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation